Which GLP-1 Is Best for Weight Loss? Semaglutide vs Tirzepatide vs Liraglutide

This article is for education only and does not constitute medical advice. It is not a substitute for professional evaluation by a licensed clinician. It does not recommend, endorse, or evaluate any specific medication, brand, dosing regimen, or treatment plan. Decisions about GLP-1 therapy belong with a licensed prescriber who knows your medical history.

---

Ask three clinics which GLP-1 is best for weight loss and you may get three different answers. That is not evasion. It is the honest state of the evidence.

There is no universal best. The right GLP-1 depends on your clinical profile, your insurance coverage and out-of-pocket budget, your tolerance for gastrointestinal side effects, how you feel about injection frequency, and what other health conditions you are managing. What the research can tell you is how the three FDA-approved options — semaglutide, tirzepatide, and liraglutide — compare on the dimensions that matter, so you can walk into a prescriber conversation with the right questions.

This guide covers all three in order of evidence depth, explains what the head-to-head trials actually showed, and flags where marketing language outruns the data. For the broader picture — including non-GLP-1 medications like phentermine/topiramate and bupropion/naltrexone — see our evidence-based comparison of the best weight loss medications.

---

The Three Contenders at a Glance

	Semaglutide	Tirzepatide	Liraglutide
Brand (weight loss indication)	Wegovy	Zepbound	Saxenda
Also approved for	Type 2 diabetes (Ozempic), CV risk reduction in obesity (Wegovy)	Type 2 diabetes (Mounjaro)	Type 2 diabetes (Victoza)
Injection frequency	Once weekly	Once weekly	Once daily
Mechanism	GLP-1 receptor agonist	Dual GIP/GLP-1 receptor agonist	GLP-1 receptor agonist
Mean weight loss in pivotal obesity trials	~15% at 68 weeks (STEP 1)1	~21% at 72 weeks (SURMOUNT-1)2	~8% at 56 weeks (SCALE)3
Dosing schedule	Weekly titration over ~16–20 weeks to 2.4 mg	Weekly titration over ~20 weeks to 15 mg	Daily titration over ~5 weeks to 3.0 mg
Weight loss FDA approval	2021	2023	2014

The pattern is clear: tirzepatide leads on average trial weight loss, semaglutide follows, and liraglutide — the oldest of the three — trails. But average trial results are not individual predictions, and efficacy is only one dimension of the decision.

---

Semaglutide: The Deepest Evidence Base

Semaglutide is the GLP-1 receptor agonist with the longest and broadest clinical trial record in obesity. If you want the medication whose evidence base has been examined from the most angles — weight loss magnitude, maintenance, cardiovascular outcomes, real-world use, and direct head-to-head comparison — semaglutide is the reference standard.

The STEP trial program

The STEP (Semaglutide Treatment Effect in People with Obesity) program is the foundation. STEP 1, published in the New England Journal of Medicine in 2021, randomized adults with obesity or overweight to once-weekly semaglutide 2.4 mg or placebo for 68 weeks. Mean weight loss was approximately 14.9% versus 2.4% with placebo — the result that established once-weekly GLP-1 therapy as a first-line obesity pharmacotherapy.¹

Follow-on trials filled in the picture. STEP 4 showed that participants who continued semaglutide after a 20-week run-in kept losing weight, while those switched to placebo regained — evidence that ongoing treatment matters.⁴ The STEP 1 extension followed participants for a year after treatment withdrawal and found that roughly two-thirds of the lost weight returned — the data behind the now-standard guidance that GLP-1 therapy is a long-term commitment, not a short course.⁵

Cardiovascular outcomes

The SELECT trial extended semaglutide's evidence base beyond weight. In adults with obesity or overweight and established cardiovascular disease but without diabetes, semaglutide 2.4 mg produced a 20% relative risk reduction in major adverse cardiovascular events — a result that led to the FDA adding a cardiovascular indication to Wegovy's label.⁶ No other GLP-1 has an equivalent obesity-population CV outcomes trial as of September 2026.

Head-to-head against liraglutide

STEP 8 compared semaglutide 2.4 mg directly against liraglutide 3.0 mg in adults without diabetes. Semaglutide produced roughly 16% mean weight loss versus about 6% with liraglutide — a decisive margin that effectively retired liraglutide as the default choice for new obesity prescriptions, though liraglutide retains niche uses.⁷

Who semaglutide tends to fit: Patients who want the deepest evidence base, those with cardiovascular disease who may benefit from the SELECT indication, and those comfortable with once-weekly injections. The once-weekly schedule is also the easiest adherence profile of the three.

---

Tirzepatide: The Efficacy Leader

Tirzepatide is not a GLP-1 receptor agonist in the strict sense. It is a dual agonist — it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. That dual mechanism appears to be the reason it produces the largest average weight loss of any approved obesity medication.

The SURMOUNT program

SURMOUNT-1, published in NEJM in 2022, randomized adults with obesity or overweight to tirzepatide at 5, 10, or 15 mg or placebo for 72 weeks. At the highest dose, mean weight loss reached approximately 21% — a result that exceeded every prior pharmacotherapy trial and reframed expectations for what medication-assisted weight loss could look like.²

SURMOUNT-4 extended the evidence to maintenance: participants who continued tirzepatide maintained their weight loss, while those switched to placebo regained.⁸ A 2025 NEJM follow-up (SURMOUNT-5) showed tirzepatide's superiority over semaglutide 2.4 mg in participants with obesity and type 2 diabetes — a head-to-head result that, for patients who qualify for both, often settles the semaglutide-or-tirzepatide question on efficacy grounds alone.⁸

The practical tradeoffs

Tirzepatide's titration schedule runs to 20 weeks at the highest dose — longer than semaglutide's — and GI side effects (nausea, diarrhea, vomiting) are the most common reason for dose holds. A 2026 systematic review and meta-analysis of GI adverse events across five GLP-1-class agents found that tolerability profiles differ meaningfully between drugs, and individual response is not predictable from trial averages.⁹ Cost and insurance coverage also vary: because tirzepatide is newer, some formularies still place it in a higher tier than semaglutide.

Who tirzepatide tends to fit: Patients whose primary goal is maximum average weight reduction and who can access it affordably. The once-weekly schedule matches semaglutide's. Patients who plateau on semaglutide sometimes switch — see our guide to switching from semaglutide to tirzepatide for what the transition involves.

---

Liraglutide: The Older Option With a Narrower Role

Liraglutide was the first GLP-1 receptor agonist approved specifically for weight management (as Saxenda, 2014), and its SCALE trial program established daily GLP-1 dosing as viable for obesity. SCALE (published in NEJM in 2015) showed approximately 8% mean weight loss at 56 weeks with liraglutide 3.0 mg — roughly half of semaglutide's result and about a third of tirzepatide's.³

Where liraglutide retains relevance:

• Pediatric obesity. Liraglutide has an FDA indication for weight management in adolescents 12 and older — a population where semaglutide and tirzepatide have more limited or no labeling.
• Tolerability screening. Because liraglutide's half-life is short (daily dosing), GI side effects resolve quickly after discontinuation. Some clinicians use it as a tolerability probe before committing a patient to a long-acting agent, though this is a practice pattern rather than a guideline recommendation.
• Cost and formulary position. As an older drug with generic competition in some channels, liraglutide can be substantially cheaper, and some insurance plans that exclude newer GLP-1s will cover it.

The once-daily injection schedule is the most demanding adherence profile of the three, and STEP 8's head-to-head result means liraglutide is rarely the first choice for adults starting GLP-1 therapy for weight loss in 2026.⁷

---

Retatrutide: Investigational Only

Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, has attracted outsized attention — including from our own three-way comparison with semaglutide and tirzepatide. Its Phase 2 trial showed mean weight loss approaching 24% at the highest dose over 48 weeks, and Phase 3 results reported in company press releases have suggested even higher figures.¹⁰

Here is the constraint: retatrutide is investigational. It has no FDA approval for any indication, no established safety record at population scale, and no pharmacy supply. Any clinic offering retatrutide today is operating outside the approved-drug framework. It may become the most effective obesity medication ever approved — the Phase 2 data are genuinely striking — but "best" requires evidence, availability, and a prescriber who can actually write for it. Retatrutide has none of the three as of September 2026.

---

How to Think About "Best": The Five Factors

The clinical trials establish a hierarchy of average efficacy. Individual decisions run through five filters:

1. Clinical profile. Cardiovascular disease history, diabetes status, kidney function, pregnancy plans, personal or family history of medullary thyroid carcinoma, and current medications all shift the risk-benefit calculation. This is the filter only a prescriber can apply.
2. Insurance and cost. Coverage for GLP-1s for weight loss (as opposed to diabetes) remains inconsistent. A medication you cannot afford to stay on is not the best medication — the STEP 1 extension data show what happens when treatment stops.⁵
3. Side-effect tolerance. Nausea, vomiting, diarrhea, and constipation affect a meaningful fraction of patients on all three drugs, with dose-dependent severity.⁹ If you have a history of GI conditions — gastroparesis, severe GERD, IBD — that history matters to drug selection.
4. Injection frequency. Once weekly (semaglutide, tirzepatide) versus once daily (liraglutide) is not a trivial difference. Adherence over months and years is where real-world results diverge from trial results.
5. Surgical and procedural plans. If you have an upcoming surgery, endoscopy, or procedure under sedation, your GLP-1's effect on gastric emptying changes the anesthesia risk conversation. Our GLP-1 perioperative safety guide covers what to tell your surgical team and when.

For patients in the Dallas–Fort Worth area evaluating these options, a structured medical evaluation — labs, history, medication review — is the starting point, whether in person or through telemedicine. The same evaluation framework applies nationally.

---

What About GLP-1 Supplements?

Search results for "best GLP-1" increasingly surface supplement pages alongside medication pages. These are not the same category, and the difference matters. No supplement contains GLP-1, mimics GLP-1 at pharmacological doses, or has trial evidence approaching even liraglutide's results. We cover the evidence honestly in our guide to GLP-1 supplements for weight loss — including what berberine and other ingredients can and cannot do, and why the "natural GLP-1 booster" framing blurs a regulatory line.

---

The Decision Framework in Practice

If you are starting the conversation with your prescriber, the evidence-based sequence looks like this:

• Maximum average efficacy, good access: tirzepatide leads the trial data.
• Deepest evidence base, cardiovascular indication: semaglutide is the reference standard.
• Adolescent indication, cost-constrained, or tolerability concerns: liraglutide retains a role.
• Already on one and plateauing, or struggling with side effects: switching is an established conversation — see our switching guide for what the evidence supports.
• Curious about retatrutide: it is investigational. Full stop.

The best GLP-1 for weight loss is the one your prescriber can justify for your specific clinical picture, that you can afford to stay on, and that you can tolerate long enough for the trial-data averages to have any chance of applying to you.

---

FAQ

Which GLP-1 is best for weight loss?

On average trial results, tirzepatide produces the largest mean weight loss (~21% in SURMOUNT-1), followed by semaglutide (~15% in STEP 1), then liraglutide (~8% in SCALE).¹²³ But "best" is not a trial-average question — it depends on your clinical profile, insurance coverage, side-effect tolerance, and injection-frequency preference. A medication you cannot tolerate or afford to continue is not the best medication for you, regardless of trial data.

Semaglutide or tirzepatide — which should I choose?

The 2025 SURMOUNT-5 head-to-head trial showed tirzepatide outperforming semaglutide 2.4 mg on weight reduction in participants with obesity and type 2 diabetes.⁸ For patients without diabetes, the network meta-analysis evidence consistently ranks tirzepatide higher on efficacy.¹¹ Semaglutide counters with a longer real-world track record, the SELECT cardiovascular indication, and in some markets better formulary position. The right choice is the one your prescriber can match to your full clinical picture and that you can sustain.

What is the GLP-1 dosage schedule for weight loss?

All three drugs use gradual dose escalation to minimize GI side effects. Semaglutide for weight loss (Wegovy) titrates from 0.25 mg to a 2.4 mg maintenance dose over approximately 16–20 weeks. Tirzepatide (Zepbound) escalates from 2.5 mg to a maximum of 15 mg over about 20 weeks. Liraglutide (Saxenda) starts at 0.6 mg daily and reaches 3.0 mg in about 5 weeks. Specific titration decisions belong with your prescriber — this is a general overview, not dosing guidance.

Is liraglutide still worth considering in 2026?

For most adults starting GLP-1 therapy for weight loss, semaglutide or tirzepatide are the default options based on efficacy data.⁷ Liraglutide retains a role for adolescents (it has a pediatric weight-management indication), for patients with formulary restrictions that exclude newer agents, and in some clinician judgment contexts where its short half-life is an advantage. It is rarely the first choice for new adult prescriptions.

Can I switch GLP-1s if one isn't working?

Switching between GLP-1s is an established clinical practice, most commonly from semaglutide to tirzepatide. It requires prescriber supervision — there is no standardized crossover protocol, and the washout and re-titration approach varies by individual. Our switching guide covers what the evidence supports and what to discuss with your prescriber.

Is retatrutide available?

No. Retatrutide is investigational as of September 2026 — no FDA approval, no pharmacy supply, no established safety record at population scale. Phase 2 results are promising,¹⁰ but any product marketed as retatrutide today is not an FDA-approved medication. No recommendation can be made for or against it.

---

Related Reading

• Best Weight Loss Medication: An Evidence-Based Comparison — the broader picture, including non-GLP-1 options
• Semaglutide vs Liraglutide — the full pairwise breakdown
• Tirzepatide vs Semaglutide — the head-to-head detail
• Semaglutide vs Tirzepatide vs Retatrutide — the investigational pipeline
• Switching From Semaglutide to Tirzepatide — the transition guide
• GLP-1 Perioperative Safety Guide — surgery and anesthesia considerations
• Best GLP-1 Supplement for Weight Loss — the supplement evidence, honestly framed

---

Sources

---

LuxeFit Wellness is a cash-pay wellness clinic serving the Dallas–Fort Worth area and patients nationwide through telemedicine. This content is educational only and does not constitute medical advice. It does not recommend, endorse, or evaluate any specific medication, brand, or dosing regimen. Decisions about GLP-1 therapy belong with a licensed prescriber who knows your medical history.

You built it. We optimize it.